Omeros
About OmerosPipelineInvestorsNews


Management

The members of Omeros' management team contribute diverse expertise across all aspects of our scientific and corporate strategies. They provide Omeros with proven leadership to navigate the complex terrain of biopharmaceutical development and commercialization.

Gregory A. Demopulos, M.D.
Chairman and Chief Executive Officer
Gregory A. Demopulos, M.D.
Chairman and Chief Executive Officer


Gregory A. Demopulos, M.D. founded our company and has served as our president, chief executive officer and chairman of the board of directors since June 1994. Prior to founding Omeros, Dr. Demopulos completed his residency in orthopedic surgery at Stanford University and his fellowship training in hand and microvascular surgery at Duke University. Dr. Demopulos currently serves on the board of trustees of the Smead Funds Trust, an open-end mutual fund company registered under the Investment Com... 
Leonard M. Blum
Chief Business and Commercial Officer
Leonard M. Blum
Chief Business and Commercial Officer


Leonard M. Blum joined Omeros as our chief business and commercial officer in April 2016. Mr. Blum brings over 28 years of executive and management experience in the pharmaceutical industry. Mr. Blum served as senior vice president, chief commercial officer from 2007 until March 2016 at Theravance, Inc., a publicly traded biopharmaceutical company, and its spin-off Theravance BioPharma, also a publicly traded biopharmaceutical company. Prior to that, Mr. Blum founded and led the commercial funct... 
Christopher S. Bral, Ph.D.
Vice President, Nonclinical Development
Christopher S. Bral, Ph.D.
Vice President, Nonclinical Development


Christopher S. Bral, Ph.D. joined Omeros as our vice president, nonclinical development in October 2015. From April 2014 to October 2015, Dr. Bral was the executive director, toxicology at Arrowhead Research Corporation. From June 2008 to April 2014, Dr. Bral served as director, drug safety evaluation at Vertex Pharmaceuticals. Prior to Vertex, Dr. Bral held various pre-clinical drug safety positions of increasing responsibility at Schering-Plough Research Institute including associate director,... 
Timothy M. Duffy
Vice President, Business Development
Timothy M. Duffy
Vice President, Business Development


Timothy M. Duffy has served as our vice president, business development since March 2010. From November 2008 to March 2010, Mr. Duffy served as the managing director of Pacific Crest Ventures, a life science consulting firm that he founded. From June 2004 through September 2008, Mr. Duffy served at MDRNA, Inc. (formerly Nastech Pharmaceutical Company, Inc.), a biotechnology company. At MDRNA, he held roles of increasing responsibility in marketing and business development, most recently as the c... 
Kenneth M. Ferguson, Ph.D.
Chief Development Officer
Kenneth M. Ferguson, Ph.D.
Chief Development Officer


Kenneth M. Ferguson, Ph.D., joined Omeros as our vice president, development in November 2010 and has served as our chief development officer since October 2012. Prior to the acquisition of ICOS Corporation in 2007 by Eli Lilly and Company, he served as vice president of therapeutic development at ICOS. Dr. Ferguson also served as chief operating officer, chief scientific officer and a member of the board of managers of Lilly ICOS LLC, the joint venture of Eli Lilly and ICOS that developed and m... 
George A. Gaitanaris, M.D., Ph.D.
Chief Scientific Officer
George A. Gaitanaris, M.D., Ph.D.
Chief Scientific Officer


George A. Gaitanaris, M.D., Ph.D. joined Omeros as our vice president, science in August 2006 and has served as our chief scientific officer since January 2012. From August 2003 to our acquisition of nura, inc. in August 2006, Dr. Gaitanaris served as the chief scientific officer of nura, a company that he co-founded and that developed treatments for central nervous system disorders. From 2000 to 2003, he served as president and chief scientific officer of Primal, Inc., a biotechnology company t... 
Michael A.  Jacobsen
Chief Accounting Officer
Michael A.  Jacobsen
Chief Accounting Officer


Mr. Jacobsen joined Omeros in August 2013 as our vice president, finance and has served as our chief accounting officer and treasurer since October 2013. Prior to joining Omeros, Mr. Jacobsen served as vice president of finance of Sarepta Therapeutics, Inc. from September 2011 to May 2013 and as its chief accounting officer from September 2011 to December 2012. From April 2007 to August 2011, Mr. Jacobsen was vice president and chief accounting officer at ZymoGenetics, Inc. Prior to his service ... 
Marcia S. Kelbon, J.D., M.S.
General Counsel and Secretary
Marcia S. Kelbon, J.D., M.S.
General Counsel and Secretary


Marcia S. Kelbon, J.D., M.S. joined Omeros as our vice president, patent and general counsel in October 2001 and has served as our secretary since September 2007. Prior to joining Omeros, Ms. Kelbon was a partner with the firm Christensen O'Connor Johnson & Kindness, PLLC, where she specialized in U.S. and international intellectual property procurement, management, licensing and enforcement issues. Ms. Kelbon received her J.D. and her M.S. in chemical engineering from the University of Washingt... 
William J. Lambert, Ph.D.
Vice President, Chemistry, Manufacturing and Controls
William J. Lambert, Ph.D.
Vice President, Chemistry, Manufacturing and Controls


William J. Lambert, Ph.D. joined Omeros as our vice president, chemistry, manufacturing and controls in January 2015. From October 2011 to January 2015, Dr. Lambert headed the Innovative Drug Delivery Group of MedImmune, the global biologics research and development arm of AstraZeneca. From January 2006 to September 2011, Dr. Lambert served as senior vice president of pharmaceutical development at Pacira Pharmaceuticals. Prior to Pacira, Dr. Lambert directed drug delivery, product development an... 
Catherine A. Melfi, Ph.D.
Chief Regulatory Officer
Catherine A. Melfi, Ph.D.
Chief Regulatory Officer


Catherine A. Melfi, Ph.D. joined Omeros as our vice president, regulatory affairs and quality systems in October 2012 and has served as our chief regulatory officer since April 2016. Dr. Melfi previously served from 1996 to 2012 at Eli Lilly and Company, where she held technical and leadership roles of increasing scope and responsibility, including as Senior Director and Scientific Director in Global Health Outcomes and Regulatory Affairs, respectively. Prior to joining Lilly, Dr. Melfi held var... 
Patricia Sandler
Vice President, Sales and Marketing
Patricia Sandler
Vice President, Sales and Marketing


Patricia Sandler joined Omeros in May 2014 as our national sales director and has served as our vice president, sales and marketing since November 2014. From October 2007 through September 2013, Ms. Sandler served in sales and marketing roles at Sunovion Pharmaceuticals, Inc., including leading a national allergy/asthma sales team from December 2010 to September 2013, managing the Lunesta brand as executive director for central nervous system product marketing from June 2009 to December 2010 and... 
J. Steven Whitaker M.D., J.D.
Chief Medical Officer
J. Steven Whitaker M.D., J.D.
Chief Medical Officer


J. Steven Whitaker, M.D., J.D. joined Omeros as our vice president, clinical development and chief medical officer in March 2010. From May 2008 to March 2010, Dr. Whitaker served as the chief medical officer, vice president of clinical development at Allon Therapeutics, Inc., a biotechnology company focused on developing drugs for neurodegenerative diseases. From August 2007 to May 2008, he served as a medical consultant to Accelerator Corporation, a biotechnology investment and development comp...